X4 Pharmaceuticals Inc [NASDAQ: XFOR] price plunged by -6.44 percent to reach at -$0.07. The one-year XFOR stock forecast points to a potential upside of 69.3. The average equity rating for XFOR stock is currently 1.33, trading closer to a bullish pattern in the stock
X4 Pharmaceuticals Inc [NASDAQ: XFOR] stock went on a downward path that fall over -12.40% on Thursday, amounting to a one-week price decrease of less than -5.83%. Over the last 12 months, XFOR stock dropped by -16.30%. The one-year X4 Pharmaceuticals Inc stock forecast points
X4 Pharmaceuticals Inc [NASDAQ: XFOR] price plunged by -3.94 percent to reach at -$0.05. The company report on April 2, 2024 at 4:05 PM that X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4). The options have a ten-year term and an exercise price of
X4 Pharmaceuticals Inc [NASDAQ: XFOR] gained 6.52% or 0.09 points to close at $1.47 with a heavy trading volume of 4648770 shares. The company report on April 2, 2024 at 4:05 PM that X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4). The options have
X4 Pharmaceuticals Inc [NASDAQ: XFOR] stock went on a downward path that fall over 0.00% on Monday, amounting to a one-week price increase of more than 58.13%. The company report on March 21, 2024 at 6:01 AM that X4 Pharmaceuticals Reports Fourth-Quarter and Full-Year 2023
X4 Pharmaceuticals Inc [NASDAQ: XFOR] gained 11.45% or 0.15 points to close at $1.46 with a heavy trading volume of 12698864 shares. The company report on March 21, 2024 at 6:01 AM that X4 Pharmaceuticals Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides Corporate
X4 Pharmaceuticals Inc [NASDAQ: XFOR] surged by $0.05 during the normal trading session on while it closed the day at $1.02. The company report on March 12, 2024 at 8:00 AM that X4 Pharmaceuticals to Report Fourth-Quarter and Full Year 2023 Financial Results and Host
© 2024, Powered by Smart TechOne
